Logo image of RAPT

RAPT THERAPEUTICS INC (RAPT) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:RAPT - US75382E2081 - Common Stock

35.78 USD
+0.46 (+1.3%)
Last: 12/10/2025, 12:12:21 PM
Fundamental Rating

3

RAPT gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 531 industry peers in the Biotechnology industry. While RAPT has a great health rating, there are worries on its profitability. RAPT does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

RAPT had negative earnings in the past year.
RAPT had a negative operating cash flow in the past year.
In the past 5 years RAPT always reported negative net income.
RAPT had a negative operating cash flow in each of the past 5 years.
RAPT Yearly Net Income VS EBIT VS OCF VS FCFRAPT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

The Return On Assets of RAPT (-63.74%) is worse than 60.08% of its industry peers.
Looking at the Return On Equity, with a value of -69.51%, RAPT is in line with its industry, outperforming 55.93% of the companies in the same industry.
Industry RankSector Rank
ROA -63.74%
ROE -69.51%
ROIC N/A
ROA(3y)-50.99%
ROA(5y)-46.45%
ROE(3y)-60.69%
ROE(5y)-53.99%
ROIC(3y)N/A
ROIC(5y)N/A
RAPT Yearly ROA, ROE, ROICRAPT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60

1.3 Margins

RAPT does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RAPT Yearly Profit, Operating, Gross MarginsRAPT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K -4K -5K

More info and screens

8

2. Health

2.1 Basic Checks

Compared to 1 year ago, RAPT has more shares outstanding
The number of shares outstanding for RAPT has been increased compared to 5 years ago.
RAPT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
RAPT Yearly Shares OutstandingRAPT Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M
RAPT Yearly Total Debt VS Total AssetsRAPT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

An Altman-Z score of 35.86 indicates that RAPT is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 35.86, RAPT belongs to the best of the industry, outperforming 95.29% of the companies in the same industry.
There is no outstanding debt for RAPT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 35.86
ROIC/WACCN/A
WACCN/A
RAPT Yearly LT Debt VS Equity VS FCFRAPT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

RAPT has a Current Ratio of 12.04. This indicates that RAPT is financially healthy and has no problem in meeting its short term obligations.
RAPT has a Current ratio of 12.04. This is amongst the best in the industry. RAPT outperforms 86.44% of its industry peers.
RAPT has a Quick Ratio of 12.04. This indicates that RAPT is financially healthy and has no problem in meeting its short term obligations.
RAPT has a Quick ratio of 12.04. This is amongst the best in the industry. RAPT outperforms 86.44% of its industry peers.
Industry RankSector Rank
Current Ratio 12.04
Quick Ratio 12.04
RAPT Yearly Current Assets VS Current LiabilitesRAPT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 50.09% over the past year.
EPS 1Y (TTM)50.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%82.71%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 10.53% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y89.63%
EPS Next 2Y36.47%
EPS Next 3Y22.56%
EPS Next 5Y10.53%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
RAPT Yearly Revenue VS EstimatesRAPT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2030 2031 2032 200M 400M 600M 800M
RAPT Yearly EPS VS EstimatesRAPT Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 10 -10 -20

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for RAPT. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RAPT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RAPT Price Earnings VS Forward Price EarningsRAPT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RAPT Per share dataRAPT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 -10

4.3 Compensation for Growth

A more expensive valuation may be justified as RAPT's earnings are expected to grow with 22.56% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.47%
EPS Next 3Y22.56%

More info and screens

0

5. Dividend

5.1 Amount

RAPT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

RAPT THERAPEUTICS INC

NASDAQ:RAPT (12/10/2025, 12:12:21 PM)

35.78

+0.46 (+1.3%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06 2025-11-06/bmo
Earnings (Next)03-04 2026-03-04/amc
Inst Owners55.17%
Inst Owner Change-2.14%
Ins Owners0.24%
Ins Owner Change0%
Market Cap991.46M
Revenue(TTM)N/A
Net Income(TTM)-105.64M
Analysts81.25
Price Target59.39 (65.99%)
Short Float %4.4%
Short Ratio2.13
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)16.19%
Min EPS beat(2)0.82%
Max EPS beat(2)31.56%
EPS beat(4)3
Avg EPS beat(4)-31.54%
Min EPS beat(4)-200.44%
Max EPS beat(4)41.9%
EPS beat(8)7
Avg EPS beat(8)-11.46%
EPS beat(12)9
Avg EPS beat(12)-7.23%
EPS beat(16)13
Avg EPS beat(16)-3.16%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)3.97%
PT rev (3m)140.92%
EPS NQ rev (1m)14.55%
EPS NQ rev (3m)18.02%
EPS NY rev (1m)15.62%
EPS NY rev (3m)24.75%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 6.52
P/tB 6.52
EV/EBITDA N/A
EPS(TTM)-11.06
EYN/A
EPS(NY)-3.42
Fwd EYN/A
FCF(TTM)-3.13
FCFYN/A
OCF(TTM)-3.12
OCFYN/A
SpS0
BVpS5.48
TBVpS5.48
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -63.74%
ROE -69.51%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-50.99%
ROA(5y)-46.45%
ROE(3y)-60.69%
ROE(5y)-53.99%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 8.64%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 12.04
Quick Ratio 12.04
Altman-Z 35.86
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)61.2%
Cap/Depr(5y)59.06%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)50.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%82.71%
EPS Next Y89.63%
EPS Next 2Y36.47%
EPS Next 3Y22.56%
EPS Next 5Y10.53%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y2.06%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year26.95%
EBIT Next 3Y-6.03%
EBIT Next 5YN/A
FCF growth 1Y7.06%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y6.03%
OCF growth 3YN/A
OCF growth 5YN/A

RAPT THERAPEUTICS INC / RAPT FAQ

What is the fundamental rating for RAPT stock?

ChartMill assigns a fundamental rating of 3 / 10 to RAPT.


What is the valuation status of RAPT THERAPEUTICS INC (RAPT) stock?

ChartMill assigns a valuation rating of 1 / 10 to RAPT THERAPEUTICS INC (RAPT). This can be considered as Overvalued.


Can you provide the profitability details for RAPT THERAPEUTICS INC?

RAPT THERAPEUTICS INC (RAPT) has a profitability rating of 0 / 10.